|
|
|
A novel cataplasma matrix of traditional Chinese
medicine |
| Jing TIAN1,Xiaolei ZHANG2,Xueqin ZHOU2, |
| 1.Research Center of Traditional
Chinese Medicine, Tianjin University of Traditional Chinese Medicine,
Tianjin 300193, China；Engineering Research
Center of Modern Chinese Medicine Discovery and Preparation Technique,
Ministry of Education, Tianjin 300193, China; 2.School of Chemical Engineering
and Technology, Tianjin University, Tianjin 300072, China; |
|
|
|
|
Abstract The aim of this paper was to develop a cataplasma matrix that can be applicable to both watersoluble and liposoluble drugs. The gellan gum and konjaku were employed as the scaffold materials of the matrix. With polyacrylic acid sodium and oligosaccharides as tacktifier, the formula of the cataplasma matrix was optimized in the orthogonal method as: gellan gum 0.4 g, xanthan€gum 0.03 g, konjac glue 0.1 g, glycerin 4 g, Gluco-Adhesive T (GAT) 6 g, Gluco-Adhesive E (GAE) 6 g, polyacrylic acid sodium 0.22 g, and sorbitol 3 g. The 180° peel strength, the tensile strength and the elongation at break was 3.043 N, 0.275 MPa and 91.05%, respectively. Furthermore, the drug-compatibilities of the matrix were investigated with baicalin, berberine and curcumin, which were used as the models of hydrophilic, poor-water-soluble and hydrophobic ingredients. The drug contents could reach 4.12% , 2.42% and 3.75%, while the in vitro release rate were measured as, 361.79, 55.85 and 104.41 μg·cm−2·h−1 for baicalin, berberine and curcumin, respectively. These results indicated that the obtained matrix had good drug-compatibility and drug-release properties for different ingredients.
|
|
Issue Date: 05 March 2010
|
|
|
Miller M A, Pisani E. The cost of unsafe injections. Bull World Health Organ, 1999, 77: 808–811
|
|
Mark R P, Robert L. Transdermal drug delivery. Nat Biotechnol, 2008November, 26(11): 1261–1268
doi: 10.1038/nbt.1504
|
|
Amanda M B, Kelly M S. Optimizing transdermal drugtherapy. Am Health-Syst Pharm, 2008, 65: 1337–1346
doi: 10.2146/ajhp070554
|
|
Zhao B, Song X H, Wang F. Hydrophilic cataplasma matrix of Traditional ChineseMedicine. Chinese Archives of TraditionalChinese Medicine, 2008, 26(6): 1276–1278
|
|
Li Y, He W, Chang C, He Y H, He P P. Study on matrix of hydrophilic cataplasm. China pharmacist, 2006, 9(10): 911–913 (in Chinese)
|
|
Zhang I, Shung K K, Edwards D A. Hydrosels with enhanced mass transfer transdemal drug. Pharm Sci, 1996, 85(2): 1312–1316
doi: 10.1021/js9601142
|
|
Zhang H, Niu X, Yang X Z. Optimization on formula ratio of matrix in Naru23 Cataplasmthrough orthogonal test. Journal of BeijingUniversity of Traditional Chinese Medicine, 2008, 31(5): 338–339 (in Chinese)
|
|
Jia W, Gao W Y, Wang T, Liu Y B, Xue J, Xiao P G. Cataplasma of traditional Chinese medicine. J China Journal of Chinese Materia Medica, 2003, 28(1): 10– 11(in Chinese)
|
|
Song J C, Huang L, Chen J L. Study on preparation and in vitro release behavior of lung targeting hydroxycamptothecin liposomes. Chinese Journal of Immunology, 2008, 43: 1564–1568 (in Chinese)
|
|
Zhou X Q, Liu H Y, Zhao T. Preparation of baicalin cataplasma. Fine Chemicals, 2007, 24(8): 778–780 (in Chinese)
|
|
Mei C L, Zhou J. Practical Statistical Method. Beijing: Science Press, 2002 (in Chinese)
|
|
Zhen P, Fan X J, Ma L, Guan Z, Lu W, Hu X. Applicationof fuzzy analytical method in the optimization of liposome preparationby orthogonal experiments. Journal of ChinesePharmaceutical Sciences, 2008, 18: 37–42 (in Chinese)
|
|
R Potts R O, McNeill S C , Desbonnet C R,Wakshull E. Transdermaldrug transport and metabolism II. The role of competing kinetic events. Pharmaceutical Research, 1989, 6(2): 119–124
doi: 10.1023/A:1015924408193
|
|
Lee P S. Transdermal hormone therapy and bone health. Clinical Interventions in Aging, 2008: 3(1) : 51–54
|
|
Hao B H, Ma L, Xu H R. The research for the absorption function of fragranttraditional Chinese medicine drug to capsaicin. Nat Prod Res Dev, 2006, 18: 637–639
|
|
Teske J, Weller J P, Larsch K, Tröger H D, Karst M. Fatal outcome in a childafter ingestion of a transdermal fentanyl patch. Int J Legal Med, 2007, 121: 147–151
doi: 10.1007/s00414-006-0137-3
|
|
Rudolf L. Transdermal buprenorphine in the management of persistent pain—safety aspects. Therapeutics and Clinical Risk Management,2006: 2(1): 115–125
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
